Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia

Charlotte Beaudart, Emmanuel Biver, Jean-Yves Reginster, René Rizzoli, Yves Rolland, Ivan Bautmans, Jean Petermans, Sophie Gillain, Fanny Buckinx, Nadia Dardenne, Olivier Bruyère, Charlotte Beaudart, Emmanuel Biver, Jean-Yves Reginster, René Rizzoli, Yves Rolland, Ivan Bautmans, Jean Petermans, Sophie Gillain, Fanny Buckinx, Nadia Dardenne, Olivier Bruyère

Abstract

Background: A specific self-administrated health-related quality of life questionnaire for sarcopenia, the Sarcopenia and Quality Of Life (SarQoL®), has been recently developed. This questionnaire is composed of 55 items translated into 22 questions and organized into seven domains of quality of life. The objective of the present work is to evaluate the psychometric properties (discriminative power, validity, reliability, floor and ceiling effects) of the SarQoL® questionnaire.

Methods: Sarcopenic subjects were recruited in an outpatient clinic in Liège, Belgium and were diagnosed according to the algorithm developed by the European Working Group on Sarcopenia in Older People. We compared the score of the SarQoL® between sarcopenic and non-sarcopenic subjects using a logistic regression after adjustment for potential confounding variables. Internal consistency reliability was determined using Cronbach's alpha coefficient; construct validity was assessed using convergent and divergent validities. Test-retest reliability was verified after a two-week interval using the intra-class correlation coefficient (ICC). At last, floor and ceiling effects were also tested.

Results: A total of 296 subjects with a median age of 73.3 (68.9-78.6) years were recruited for this study. Among them, 43 were diagnosed sarcopenic. After adjustment for potential confounding factors, the total score and the scores of the different dimensions of the SarQoL® questionnaire were significantly lower for sarcopenic than for non-sarcopenic subjects (54.7 (45.9-66.3) for sarcopenic vs. 67.8 (57.3 - 79.0) for non sarcopenic, OR 0.93 (95%CI 0.90-0.96)). Regarding internal consistency, the Cronbach's alpha coefficient was 0.87. The SarQoL® questionnaire data showed good correlation with some domains of the Short-Form 36 (SF-36) and the EuroQoL 5-dimension (EQ-5D) questionnaires and with the mobility test. An excellent agreement between the test and the retest was found with an ICC of 0.91 (95% CI 0.82-0.95). At last, neither floor nor ceiling effects were detected.

Conclusions: The SarQoL® questionnaire is valid, consistent, and reliable and can therefore be recommended for clinical and research purposes. However, its sensitivity to change needs to be assessed in future longitudinal studies.

Keywords: Psychometric validation; Quality of life; Questionnaire; SarQoL®; Sarcopenia.

© 2016 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.

References

    1. Cruz‐Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–423.
    1. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755–763.
    1. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, et al Age‐associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003;95:1851–1860.
    1. Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc 2006;54:56–62.
    1. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, et al Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well‐functioning older persons. J Gerontol A Biol Sci Med Sci 2005;60:324–333.
    1. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50:889–896.
    1. Rantanen T. Muscle strength, disability and mortality. Scand J Med Sci Sport 2003;13:3–8.
    1. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 2010;21:543–559.
    1. Beaudart C, Rizzoli R, Bruyere O, Reginster JY, Biver E. Sarcopenia: burden and challenges for public health. 2014. Archives of Public Health. Arch. Public Heal. 2014;72:45.
    1. Silva Neto LS, Karnikowiski MG, Tavares AB, Lima RM. Association between sarcopenia, sarcopenic obesity, muscle strength and quality of life variables in elderly women. Rev Bras Fisioter 2012;16:360–367.
    1. Yadav A, Chang Y‐H, Carpenter S, Silva AC, Rakela J, Aqel BA, et al Relationship between sarcopenia, six‐minute walk distance and health‐related quality of life in liver transplant candidates. Clin Transplant 2015;29:134–141.
    1. Beaudart C, Reginster JY, Petermans J, Gillain S, Quabron A, Locquet M, et al Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Exp Gerontol 2015;69:103–110.
    1. Morishita S, Kaida K, Tanaka T, Itani Y, Ikegame K, Okada M, et al Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health‐related quality of life in patients before allogeneic hematopoietic stem cell transplantation. Support Care Cancer 2012;20:3161–318.
    1. Rizzoli R, Reginster JY, Arnal JF, Bautmans I, Beaudart C, Bischoff‐Ferrari H, et al Quality of life in sarcopenia and frailty. Calcif Tissue Int 2013;101–120.
    1. Beaudart C., Biver E., Reginster J.‐Y., Rizzoli R., Rolland Y., Bautmans I., Petermans J., Gillain S., Buckinx F., Van Beveren J., Jacquemain M., Italiano P., Dardenne N OB. Development of a self‐administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age ageing, Submitt. Publ. 2015.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297–334.
    1. Nunnally JC BI. Psychometric theory New York: McGrawHill Inc; 1994. Available from: .
    1. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991;12:142S–158S.
    1. Terwee CB, Bot SDM, de Boer MR, van der Windt DAWM, Knol DL, Dekker J, et al Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34–42.
    1. Syddall HE, Martin HJ, Harwood RH, Cooper C, Aihie Sayer A. The SF‐36: a simple, effective measure of mobility‐disability for epidemiological studies. J Nutr Heal Aging 2009;13:57–62.
    1. Rabin R, de Charro F. EQ‐5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–343.
    1. Avlund K, Kreiner S, Schultz‐Larsen K. Construct validation and the Rasch model: functional ability of healthy elderly people. Scand J Soc Med 1993;21:233–246.
    1. Tombaugh TN, McIntyre NJ. The mini‐mental state examination: a comprehensive review. J Am Geriatr Soc 1992;40:922–935.
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle.: update 2015. J Cachexia Sarcopenia Muscle 2015;6:315–316.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe